PRESS RELEASE published on 10/06/2025 at 16:35, 1 month 29 days ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech SA declares the number of shares and voting rights comprising the issued capital. Total shares: 97,330,405. Total voting rights: 165,543,792 Voting Rights Shares Sartorius Stedim Biotech Regulatory Filing Issued Capital
BRIEF published on 09/02/2025 at 09:27, 3 months 2 days ago Sartorius Stedim Biotech Declaration on Share Capital and Voting Rights Share Capital Voting Rights Actions Regulation Sartorius Stedim
PRESS RELEASE published on 09/02/2025 at 09:23, 3 months 2 days ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech S.A. declares the number of shares and voting rights in Aubagne, France. Total shares: 97,330,405, total voting rights: 165,495,249 Voting Rights Shares Sartorius Stedim Biotech France Aubagne
PRESS RELEASE published on 09/02/2025 at 09:22, 3 months 2 days ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech SA issued a declaration regarding the number of shares and voting rights. Total shares: 97,330,405. Total voting rights: 165,544,375 Voting Rights Capital Déclaration Shares Sartorius Stedim Biotech SA
BRIEF published on 08/04/2025 at 10:55, 4 months ago Sartorius Stedim Biotech: Number of shares and voting rights Share Capital Voting Rights Actions AMF Sartorius Stedim Biotech
PRESS RELEASE published on 08/04/2025 at 10:50, 4 months ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech SA: Declaration of the number of shares and voting rights in the issued capital as of July 31, 2025 Voting Rights Déclaration Shares Sartorius Stedim Biotech Issued Capital
BRIEF published on 07/22/2025 at 07:07, 4 months 14 days ago Sartorius Stedim Biotech Releases H1 2025 Financial Report Business Development Biopharmaceutical Industry Half-year Results Sartorius Stedim 2025 Financial Report
BRIEF published on 07/22/2025 at 07:05, 4 months 14 days ago Sartorius Stedim Biotech Reports Solid Half-Year 2025 Results Profitability Sales Growth Sartorius Stedim Biotech Biopharmaceutical Industry Half-year Results 2025
PRESS RELEASE published on 07/22/2025 at 07:02, 4 months 14 days ago Sartorius Stedim Biotech SA: Information on Document Availability Sartorius Stedim Biotech SA releases first half 2025 results and full year forecast. Report available online with financial statements and company profile Financial Statements Investor Relations Sartorius Stedim Biotech Biopharmaceutical Industry First Half 2025 Results
PRESS RELEASE published on 07/22/2025 at 07:00, 4 months 14 days ago Half-year results 2025 of Sartorius Stedim Biotech Sartorius Stedim Biotech reports strong half-year results for 2025 with sales revenue up 9.4% in constant currencies and underlying EBITDA rising by 19.3% Sartorius Stedim Biotech Sales Revenue Half-year Results 2025 Underlying EBITDA
Published on 12/05/2025 at 02:35, 5 hours 28 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 7 hours 3 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 58 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 3 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 1 hour 2 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 32 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 8 hours 12 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 37 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 48 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 14 hours 3 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 18 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 14 hours 19 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 1 hour ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 14 hours ago Declaration of voting rights at the end of November 2025
